NCT03218826: PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

NCT03218826
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+
Other Mutations: PTEN, PI3K
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have PTEN or PIK3CB mutated tumor; If HR+/HER2-negative, must also be ER+
Exclusions: Patients with RAF or PIK3CA mutations; Patients with known brain metastases
https://ClinicalTrials.gov/show/NCT03218826

Comments are closed.

Up ↑